Trials / Completed
CompletedNCT01866293
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib (XL184) |
Timeline
- Start date
- 2013-05-28
- Primary completion
- 2016-08-18
- Completion
- 2016-08-18
- First posted
- 2013-05-31
- Last updated
- 2017-08-30
- Results posted
- 2017-08-30
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01866293. Inclusion in this directory is not an endorsement.